CB Pharma Acquisition Corp. Announces Record Date for Extraordinary General Meeting of Shareholders
24 May 2016 - 10:00PM
CB Pharma Acquisition Corp. (“CB Pharma”)
(NASDAQ:CNLM) (NASDAQ:CNLMU) (NASDAQ:CNLMR) (NASDAQ:CNLMW)
announced today that holders of record of CB Pharma’s ordinary
shares at the close of business on May 25, 2016 (the “Record Date”)
will be invited to attend CB Pharma’s extraordinary general meeting
of shareholders to vote on, or submit a proxy to vote on (A) a
proposal to amend CB Pharma’s amended and restated memorandum and
articles of association (the “charter”) to extend the date by which
CB Pharma has to consummate a business combination (the
“Extension”) to December 12, 2016, (B) a proposal to amend CB
Pharma’s charter to allow the holders of ordinary shares issued in
CB Pharma’s initial public offering to elect to convert their
public shares into their pro rata portion of the funds held in the
trust account established at the time of the IPO if the Extension
is implemented and (C) a proposal to change CB Pharma’s name from
“CB Pharma Acquisition Corp.” to “Origo Acquisition Corporation.”
The full meeting agenda will be detailed in the definitive proxy
statement to be mailed to all CB Pharma shareholders once ready.
The meeting of shareholders of CB Pharma has been tentatively
scheduled for June 10, 2016, which date is subject to change.
Ensuring Your Vote is Counted
In advance of the Record Date, CB Pharma advises holders of its
securities to move these securities into accounts that do not
permit the lending of securities, so called cash accounts or
segregated accounts, and out of accounts that permit the lending of
securities, such as margin accounts. These steps are designed to
ensure that votes related to ordinary shares beneficially owned by
shareholders are properly counted. Beneficial owners of ordinary
shares that have been lent out (either with or without the
beneficial owners’ knowledge) are not permitted to vote those
shares.
About CB Pharma Acquisition Corp.
CB Pharma is a Cayman Islands exempted company formed for the
purpose of entering into a merger, share exchange, asset
acquisition, share purchase, recapitalization, reorganization, or
similar business combination with one or more businesses or
entities. CB Pharma’s efforts to identify target businesses is not
limited to a particular industry or geographic region.
Safe Harbor
This press release includes “forward-looking statements” within
the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. Actual results
may differ from expectations, estimates and projections and,
consequently, you should not rely on these forward looking
statements as predictions of future events. Words such as “expect,”
“estimate,” “project,” “budget,” “forecast,” “anticipate,”
“intend,” “plan,” “may,” “will,” “could,” “should,” “believes,”
“predicts,” “potential,” “continue,” and similar expressions are
intended to identify such forward-looking statements. These
forward-looking statements involve significant risks and
uncertainties that could cause the actual results to differ
materially from the expected results.
Additional information concerning these and other risk factors
is contained in CB Pharma’s most recent filings with the SEC. All
subsequent written and oral forward-looking statements concerning
CB Pharma are expressly qualified in their entirety by the
cautionary statements above. CB Pharma cautions readers not to
place undue reliance upon any forward-looking statements, which
speak only as of the date made. CB Pharma does not undertake or
accept any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statement to reflect
any change in their expectations or any change in events,
conditions or circumstances on which any such statement is
based.
Disclaimer
This press release is not a proxy statement or solicitation of a
proxy, consent or authorization with respect to any securities or
in respect of the proposed transaction and shall not constitute an
offer to sell or a solicitation of an offer to buy the securities
of CB Pharma, nor shall there be any sale of any such securities in
any state or jurisdiction in which such offer, solicitation, or
sale would be unlawful prior to registration or qualification under
the securities laws of such state or jurisdiction.
CONTACT:
Jaclyn Jaffe
CB Pharma Acquisition Corp.
781-652-4500
Origo Acquisition Corporation (NASDAQ:OACQU)
Historical Stock Chart
From May 2024 to Jun 2024
Origo Acquisition Corporation (NASDAQ:OACQU)
Historical Stock Chart
From Jun 2023 to Jun 2024